Your session is about to expire
← Back to Search
Imatinib for COVID-19
Study Summary
This trial is testing if a drug called imatinib is safe and effective for treating people hospitalized with COVID-19. The trial is randomized, which means that people are assigned by chance to either receive imatinib or a placebo (a medicine with no active ingredient). Neither the participants nor the researchers will know who is receiving imatinib or the placebo until the trial is over.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 330 Patients • NCT03112603Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver and kidney functions are within normal limits.I am 18 or older and currently in the hospital.My blood counts are within a healthy range.You are not taking part in any other experimental drug studies. It's okay if you are using certain medications that are not officially approved for your condition, as long as they are considered standard care or have emergency approval. This includes antivirals like remdesivir that have been authorized by the FDA for emergency use.You tested positive for COVID-19 in a respiratory tract sample within the last 7 days.I can understand and am willing to sign the consent form, or my legal representative can do it if I'm too unwell.I do not have any severe illnesses that my doctor thinks would interfere with the study.
- Group 1: Imatinib
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary conditions that Imatinib is meant to treat?
"Acute lymphoblastic leukemia is often treated with Imatinib. However, this medication can also help patients with refractory acute lymphoblastic leukemia (all), muscular dystrophy, and metastatic dermatofibrosarcoma protuberans."
Has Imatinib been federally sanctioned in the United States?
"Imatinib has received a 3 for safety from our team at Power. A Phase 3 trial means that, not only is there some evidence for the medication's efficacy, but there are also multiple rounds of data affirming its safety."
How many enrollees does this research project have at full capacity?
"Yes, the most recent update on clinicaltrials.gov suggests that this study is still looking for patients. The trial was initially posted on June 2nd, 2020 and was updated on July 19th, 2020. A total of 204 individuals are needed for the study, which is taking place at a single site."
Share this study with friends
Copy Link
Messenger